Since its clinical introduction in the 1960s, levodopa (L‐dopa) has been considered a “miracle drug” for Parkinson's disease (PD). L‐Dopa is still the most effective treatment for improving cardinal motor signs in PD, including bradykinesia, rigidity, and tremor. Despite consistent...
By 2025, an estimated three‐quarters of the global population aged 60 and older will live in Latin American and Caribbean countries (LAC), leading to a rise in age‐related conditions. The main goal of the Panama Aging Research Initiative – Health Disparities (PARI‐HD) research...
Parkinson’s disease (PD) is a prevalent neurodegenerative disorder causing substantial disability and posing a global public health challenge due to its motor and non-motor symptoms (NMS) [1]. According to the 2016 Global Burden of Disease Study, Chinese patients make up approximately 23% of the...
Parkinson's disease (PD) is a debilitating condition that affects millions of people worldwide, yet there are currently no reliable biomarkers for its diagnosis. Alpha‐synuclein aggregation is a well‐known hallmark of PD pathology, but the behavior and kinetics of these aggregates are poorly...
In recent decades, epidemiological and experimental studies have looked into the role of pesticides, particularly the herbicide paraquat, in the development of Parkinson’s disease. Horseradish tree (Moringa oleifera) is an ethnobotanical plant with lots of therapeutic potential, but there...
Parkinson disease (PD) is a common neurodegenerative disease characterized by disabilities of both motor and non-motor systems. Its pathological features include loss of dopaminergic neurons in the substantia nigra, especially in the ventrolateral tier. Conventional diagnosis of idiopathic Parkinson’s...